EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study

Miquel Massons iD, Nuria Guillen, Jordi Sarto iD, Neus Falgàs, Sergi Borrego-Écija iD, Diana Esteller-Gauxax, Magda Castellví, Adrià Tort-Merino, Agnès Pérez-Millan, Anna Antonell iD, Josep M Augè Fradera, Gerard Piñol und 22 weitere

Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2268-2277

DOI: 10.1002/acn3.70387 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 13.04.2026. Verfasst von Miquel Massons und 33 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona - Institut d'Investigacion…. Hauptthemen laut MEDLINE: tau Proteins, Amyloid beta-Peptides, Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Fundació Societat Catalana de Neurologia, Generalitat de Catalunya.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Plasma tau phosphorylated at threonine 217 (p‐tau217) measured with fully automated platforms has shown high accuracy for Alzheimer's disease (AD) diagnosis, but real‐world multicenter data remain limited. We aimed to validate the diagnostic performance of p‐tau217 for identifying AD pathology in a real‐world multicenter cohort across seven memory clinics in Catalonia (Spain), with only one tertiary hospital with prior experience in AD blood‐based biomarkers.

Methods

In this prospective multicenter study, consecutive patients with cognitive impairment undergoing routine cerebrospinal fluid (CSF) biomarker testing were included. Plasma samples were collected following a standardized pre‐analytical protocol and analyzed centrally using the Lumipulse G p‐tau217 assay (Fujirebio). Diagnostic accuracy for Aβ status was assessed overall and across sites.

Results

A total of 185 participants were included. Plasma p‐tau217 showed excellent accuracy for CSF‐defined Aβ status (AUC 0.916) with consistent performance across centers. Using a single cut‐off, diagnostic accuracy reached 84.9%, which prompted the use of a dual‐threshold strategy to improve overall performance and to classify p‐tau217 values into low, intermediate, and high probability categories of Aβ positivity. When applying a strict model with 97.5% sensitivity and specificity (cut‐offs 0.146/0.486 pg/mL), 42.7% of participants fell within the intermediate zone, whereas the remaining 57.3% were confidently classified with 95.3% accuracy.

Interpretation

In a real‐world multicenter memory‐clinic cohort, plasma p‐tau217 measured on a fully automated platform accurately discriminated CSF Aβ status and enabled reliable rule‐in/rule‐out classification in over half of patients. These findings support its broader clinical use as an initial diagnostic tool for AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAmyloid beta-PeptidesAlzheimer DiseaseCognitive DysfunctionHumansFemaleMaleProspective StudiesBiomarkersAgedAged, 80 and overMiddle AgedPredictive Value of TestsSensitivity and Specificity

Stichwörter der Autor:innen

Alzheimer's diseaseblood‐based biomarkersmulticenter studyplasmap‐tau217

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkersMAPT protein, human

Autor:innen und Institutionen

  • Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • University of Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Hospital Universitari Santa Maria, Gestió Serveis Sanitaris, Lleida, Spain.
  • eHealth Center, Faculty of Computer Science, Multimedia and Telecommunications, Universitat Oberta de Catalunya, Barcelona, Spain.
  • Hospital de Figueres, Fundació Salut Empordà, Figueres, Spain.

ORCID-Profile: Miquel Massons, Jordi Sarto, Sergi Borrego-Écija, Anna Antonell, Anna Carnes-Vendrell, Raquel Sánchez-Valle, Albert Lladó

Förderung

  • Instituto de Salud Carlos III
  • Fundació Societat Catalana de Neurologia, Generalitat de Catalunya

Zitieren

APA

Massons, M., Guillen, N., Sarto, J., Falgàs, N., Borrego-Écija, S., Esteller-Gauxax, D., Castellví, M., Tort-Merino, A., Pérez-Millan, A., Antonell, A., Augè Fradera, J. M., Piñol, G., Riba, I., Carnes-Vendrell, A., Cullell, M., Osuna, M. T., Bajo, L., Romero, T., Bonjoch, E., …, & Lladó, A. (2026). Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study. Annals of Clinical and Translational Neurology, 13(11), 2268-2277. https://doi.org/10.1002/acn3.70387

Vancouver

Massons M, Guillen N, Sarto J, Falgàs N, Borrego-Écija S, Esteller-Gauxax D, et al. Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study. Annals of Clinical and Translational Neurology. 2026;13(11):2268-2277. doi:10.1002/acn3.70387

BibTeX
@article{Massons2026,
  author = {Massons, Miquel and Guillen, Nuria and Sarto, Jordi and Falgàs, Neus and Borrego-Écija, Sergi and Esteller-Gauxax, Diana and Castellví, Magda and Tort-Merino, Adrià and Pérez-Millan, Agnès and Antonell, Anna and Augè Fradera, Josep M and Piñol, Gerard and Riba, Iolanda and Carnes-Vendrell, Anna and Cullell, Marta and Osuna, Maria Teresa and Bajo, Lorena and Romero, Teresa and Bonjoch, Eva and Bello, Joan and Fernández, Susana and Balagué, Marta and Gómez-Ruiz, Isabel and Boltes, Anuncia and Pont, Claustre and Cuevas, Raquel and Carrillo, Sara and Iglesias, Laura and Casadevall Codina, Teresa Maria and Guinea, Lorena Grau and Espada, Fernando Jose and Sánchez-Valle, Raquel and Balasa, Mircea and Lladó, Albert},
  title = {Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {11},
  pages = {2268--2277},
  doi = {10.1002/acn3.70387}
}
Kostenlos starten →